Quartz Partners LLC Buys 820 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Quartz Partners LLC increased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 28,499 shares of the specialty pharmaceutical company’s stock after purchasing an additional 820 shares during the quarter. Quartz Partners LLC owned 0.05% of Supernus Pharmaceuticals worth $1,031,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Pacer Advisors Inc. increased its position in Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after acquiring an additional 403,028 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Supernus Pharmaceuticals by 145.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,864 shares of the specialty pharmaceutical company’s stock worth $6,699,000 after purchasing an additional 127,420 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Supernus Pharmaceuticals by 14.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock valued at $22,212,000 after purchasing an additional 91,354 shares during the last quarter. Geode Capital Management LLC boosted its position in Supernus Pharmaceuticals by 5.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after buying an additional 74,438 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in Supernus Pharmaceuticals by 40.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company’s stock worth $7,901,000 after acquiring an additional 73,118 shares in the last quarter.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN opened at $33.05 on Monday. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28. The company has a 50-day moving average of $37.48 and a 200 day moving average of $35.38. The firm has a market cap of $1.82 billion, a PE ratio of 30.89 and a beta of 0.90.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $57.00 to $36.00 in a report on Wednesday, February 19th.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 9.30% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.